Clinical Trial Update: Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) [Phase 4]

View source ↗

Summary

This Phase 4 trial update reports the completion of a study evaluating cardiovascular risk in HIV patients who switched from a boosted protease inhibitor to dol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 4 | Status: COMPLETED